Back to News
Market Impact: 0.25
Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Arcturus Therapeutics reported Q3 2026 revenue of $18.3 million, up from $17.2 million a year earlier. Revenue for the first nine months of 2026 was $23.3 million, compared with $74.8 million in the same period of 2025; the provided article text ends before further results or explanations.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.20
Ticker Sentiment
ARCT-0.35
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens